BofA Raised Syndax (SNDX) PT to $28, Cites Heavy Pre-Announcements Lowering Earnings Impact

Group 1 - Syndax Pharmaceuticals Inc. has been identified as a promising low-cost stock, with Bank of America raising its price target to $28 from $27 while maintaining a Buy rating [1][3] - The company has partnered with the World Orphan Drug Alliance to launch a Managed Access Program for its drug Revuforj (revumenib), aimed at providing access to patients in regions where the drug is not commercially available [1] - Revuforj is FDA-approved in the US for treating adult and pediatric patients with specific types of acute leukemia, which are associated with poor prognosis and limited treatment options [1] Group 2 - The Managed Access Program is designed to operate within local regulatory frameworks and requires secured funding for patients with rare and life-threatening blood cancers [1] - The collaboration aims to bridge the access gap for innovative oncology treatments and allow international physicians to gain clinical experience with Revuforj [1]